ArticleFrontiers in physiology2025
Re-ascent triggered high-altitude pulmonary and cerebral edema in a Tibetan with pre-existing high-altitude polycythemia: a Case Report.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-altitude pulmonary edema (HAPE), high-altitude cerebral edema (HACE), and high-altitude polycythemia (HAPC) are each rarely observed in Tibetan populations. The coexistence of HAPE, HACE, and HAPC in the same person has not been previously documented. Here, we report the case of a native Tibetan male with HAPC who developed both HAPE and HACE upon re-ascent to an altitude of 3,650 m after a 27-day stay at low altitude. On the 3rd-4th day post-return, the patient exhibited persistent dyspnea, chest tightness, hypersomnia, intermittent agitation, and confusion. Chest CT and multimodal neuroimaging confirmed the presence of HAPE and HACE. Treatment followed guidelines (supplemental oxygen, high-dose dexamethasone) along with supportive measures, resulting in clinical resolution. This is the first reported case of co-occurring HAPE, HACE and HAPC in a native Tibetan upon re-ascent, suggesting that pre-existing HAPC may be a significant risk factor for severe acute high-altitude illness in this setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.